Press Releases Spexis AG

Equities

POLN

CH0106213793

Market Closed - Swiss Exchange Other stock markets 16:34:17 30/04/2024 BST			5-day change	1st Jan Change
0.0588 ^CHF	+15.29%		-0.34%	+43.41%

04-17	Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	MT
04-17	Swiss Court OKs Moratorium Extension for Spexis	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.	07:32pm	EQ
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera	04-17	EQ
Spexis announces closing of sale of preclinical antibiotics program to Basilea	02-08	EQ
Spexis announces sale of preclinical antibiotics program to Basilea	01-15	EQ
Spexis is Granted Debt-Restructuring Moratorium	12-05	EQ
Spexis Provides Update Regarding Debt-Restructuring Moratorium	11-29	EQ
Spexis to file an application for a debt-restructuring moratorium	11-08	EQ
Spexis Announces Changes to the Executive Committee	11-01	EQ
Spexis Announces Changes to the Executive Committee	11-01	AQ
Spexis to host business update conference call on October 9, 2023	06/10/23	EQ
Spexis to host business update conference call on October 9, 2023	06/10/23	AQ
Spexis provides business update and announces financial results for the first half of 2023	29/09/23	EQ
Spexis : Half Year Report 2023	29/09/23	PU
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology	28/09/23	EQ
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology	28/09/23	AQ
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies	15/08/23	EQ
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies	15/08/23	AQ
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions	30/06/23	EQ
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions	30/06/23	AQ
Spexis announces the results of its Annual General Meeting 2023	26/06/23	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Spexis AG

Equities

POLN

CH0106213793

Press Releases

Filters